Overall verdict
Sell
3.5/10
1-year performance
-1.38%
Score breakdown
Down 1.4% over 1 year, 91% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Growth 1.6/10.
Eurobio Scientific Société anonyme engages in research, development, and marketing specialty diagnostic products in the areas of transplantation, infectious diseases, autoimmunity, oncology, and life sciences. The company produces and markets transport and preservation media for corneal grafts ; AlloMap, for heart transplant follow up ; cell culture media, molecular biology reagents, contract manufacturing service, and proprietary antibodies ;
TQS (Tetanus Quick Stick), a rapid test used in emergency departments or pharmacies to assess the vaccination status or immune protection of patients against tetanus ; EBX molecular biology ranges in the field of infectious diseases ; and EndoPredict range, a second-generation multigene expression test for postmenopausal women with early-stage breast cancer, ER positive, and HER2 negative, as well as Prolaris.
It also provides GenDx, EurobioPlex, FungiLine, Biosafety PKA, and immunology products. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.
Sector
Health Care
Industry
Biotechnology
Primary listing
Euronext
France
CEO
Denis Fortier
Founded
1997
Employees
343
Revenue / employee
491 531 EUR
Next earnings
—
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
25.70 EUR
52-week low
19.30 EUR
1-year performance
-1.38%
Declining
Year-to-date performance
1.62%
Declining
Drawdown
-2.33%
Near its high
Position in the 52-week range
91% of range
Range: 30.00 EUR - 30.00 EUR (2 methods agree)
The price implies growth of 18.34% per year; the company grows at -10.00%.
Gross margin 43.3%, net margin 2.9%, ROIC 2.6%, ROE 2.7%.
Net margin
2.89%
Low
Sector -229.34%|S&P 12.97%
Gross margin
43.34%
High
Return on equity (ROE)
2.69%
Low
Sector -58.37%|S&P 16.52%
Return on invested capital (ROIC)
2.56%
Low
Free cash flow margin (FCF)
2.71%
Low
Profit-to-cash conversion (FCF conversion)
0.94x
High
Margin stability
11.7 pts
Very uneven
Revenue to net income
Growth
1.6/10Revenue up 4.6% over 1 year, -2.2% a year over 5, EPS -40.6% a year over 5.
Revenue (trailing 12 months)
169M EUR
Revenue growth (1y)
4.60%
Moderate
Revenue growth (3y)
10.48%
Moderate
EPS growth (1y)
—
EPS CAGR (5y)
-40.59%
Declining
EPS revisions (3 months)
0.00%
Revised down
Valuation
2.6/10P/E 51.9x, forward P/E 22.2x, EV/EBITDA 7.7x, PEG 2.46. The multiple sits in the 57th percentile of its own 5-year history.
P/E (TTM)
51.9x
Very expensive
Sector 11.3x|S&P 23.0x
Forward P/E
22.2x
Very expensive
EV / EBITDA
7.7x
Cheap
Sector 13.5x|S&P 14.5x
PEG
2.46
Very expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
30.00 EUR
Undervalued
P/E vs its own 5-year history
among the 43% highest valuations
In line with its history
Market cap
252M EUR
Financial strength
10.0/10Cash covers 129.1% of the debt, net debt/EBITDA -0.1x.
Net debt / EBITDA
-0.1x
Very solid
Gearing (net debt / equity)
-2.54%
Net cash
Cash
20.7M EUR
Cash / market cap
8.19%
Solid
Cash / total debt
129.12%
Net cash
Net debt
-4.7M EUR
Equity
183M EUR
Closed daily candles, 23 months
Last close on September 4, 2026: 19.60 EUR
- MM2020.29
- MM5020.83
- MM20022.62
- RSI 1437.6
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.82%
200-day average slope, 3 months
-4.99%
50-day average slope, 1 month
-3.71%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
1.62 % per day
Volatility change
-26.43%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.13 (1) | 1.13 (1) | 176 (1) | 32 (1) | 12 (1) |
Amounts in millions of EUR, EPS in EUR per share. In brackets, the number of analysts. Consensus as of September 18, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 2 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 3 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 4 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 5 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 6 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 7 | ALERS | 3.5 | 3.4 | 287M USD | 51.9x | 2.9 % | 4.6 % | 2.6 % | -0.1x | 1.8 % | -1.4 % | ||
| 8 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % | ||
| 9 | A174900 | 2.1 | 2.2 | 285M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.1 % | 27.3 % |
